Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of apatinib in advanced hepatocellular carcinoma
ChiCTR1800019331Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Nov 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Safety. Started Nov 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800019331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019331.